Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients

被引:100
作者
Eastell, R
Devogelaer, JP
Peel, NFA
Chines, AA
Bax, DE
Sacco-Gibson, N
de Deuxchaisnes, CN
Russell, RGG
机构
[1] No Gen Hosp, Dept Human Metab & Clin Biochem, Sheffield S5 7AU, S Yorkshire, England
[2] No Gen Hosp, Bone & Joint Res Unit, Sheffield S5 7AU, S Yorkshire, England
[3] Catholic Univ Louvain, St Luc Univ Hosp, Rheumatol Unit, Brussels, Belgium
[4] Procter & Gamble Pharmaceut, Cincinnati, OH USA
关键词
bisphosphonates; glucocorticoid-induced osteoporosis; rheumatoid arthritis; risedronate;
D O I
10.1007/s001980070122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the study was to assess risedronate's effect on bone mineral density in postmenopausal women with rheumatoid arthritis receiving glucocorticoids. We carried out a two center, 2 year, double-masked, placebo-controlled trial with a third year of nontreatment follow-up. We studied 120 women requiring long-term glucocorticoid therapy at > 2.5 mg/ day prednisolone randomized to treatment with daily placebo; daily 2.5 mg risedronate; or cyclical 15 mg risedronate (2 out of 12 weeks). At 97 weeks, bone mineral density was maintained at the lumbar spine (+1.4%) and trochanter (+0.3%) in the daily 2.5 mg risedronate group, while significant bone loss occurred in the placebo group (-1.6%, p = 0.03; and 4.0%, p<0.005, respectively). At the femoral neck, there was a nonsignificant bone loss in the daily 2.5 mg risedronate group (-1.0%) while in the placebo group bone mass decreased significantly (-3.6%, p<0.001). The difference between placebo and daily 2.5 mg risedronate groups was significant at the lumbar spine (p = 0.009) and trochanter (p = 0.02) but did not reach statistical significance at the femoral neck. Although not significantly different from placebo at the lumbar spine, the overall effect of the cyclical regimen was similar to that of the daily 2.5 mg risedronate regimen. Treatment withdrawal led to bone loss in the risedronate groups that was significant at the lumbar spine. A similar number of patients experienced adverse events (including upper gastrointestinal events) across treatment groups and risedronate was generally well tolerated. Thus risedronate preserves bone mass in postmenopausal women with rheumatoid arthritis receiving glucocorticoids while patients receiving a placebo have significant bone loss.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 27 条
[1]   Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis [J].
Adachi, JD ;
Bensen, WG ;
Brown, J ;
Hanley, D ;
Hodsman, A ;
Josse, R ;
Kendler, DL ;
Lentle, B ;
Olszynski, W ;
SteMarie, LG ;
Tenenhouse, A ;
Chines, AA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06) :382-387
[2]  
Adachi JD, 1998, ARTHRITIS RHEUM, V41, pS137
[3]  
Amin S, 1998, ARTHRITIS RHEUM, V41, pS137
[4]  
Cohen S, 1998, ARTHRITIS RHEUM-US, V41, pS137
[5]   FACTORS AFFECTING THE ASSAY OF URINARY 3-HYDROXY PYRIDINIUM CROSS-LINKS OF COLLAGEN AS MARKERS OF BONE-RESORPTION [J].
COLWELL, A ;
RUSSELL, RGG ;
EASTELL, R .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1993, 23 (06) :341-349
[6]   Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica [J].
Dolan, AL ;
Moniz, C ;
Dasgupta, B ;
Li, F ;
Mackintosh, C ;
Todd, P ;
Corrigall, V ;
Panayi, GS .
ARTHRITIS AND RHEUMATISM, 1997, 40 (11) :2022-2029
[7]   EVALUATION OF FACTORS ASSOCIATED WITH GLUCOCORTICOID-INDUCED OSTEOPENIA IN PATIENTS WITH RHEUMATIC DISEASES [J].
DYKMAN, TR ;
GLUCK, OS ;
MURPHY, WA ;
HAHN, TJ ;
HAHN, BH .
ARTHRITIS AND RHEUMATISM, 1985, 28 (04) :361-368
[8]   A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update [J].
Eastell, R ;
Reid, DM ;
Compston, J ;
Cooper, C ;
Fogelman, I ;
Francis, RM ;
Hosking, DJ ;
Purdie, DW ;
Ralston, SH ;
Reeve, J ;
Russell, RGG ;
Stevenson, JC ;
Torgerson, DJ .
JOURNAL OF INTERNAL MEDICINE, 1998, 244 (04) :271-292
[9]   Treatment of postmenopausal osteoporosis [J].
Eastell, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (11) :736-746
[10]   EXCRETION OF PYRIDINIUM CROSS-LINKS CORRELATES WITH DISEASE-ACTIVITY AND APPENDICULAR BONE LOSS IN EARLY RHEUMATOID-ARTHRITIS [J].
GOUGH, AKS ;
PEEL, NFA ;
EASTELL, R ;
HOLDER, RL ;
LILLEY, J ;
EMERY, P .
ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (01) :14-17